The irretrievable fate of neurons dominated the neuroscience rhetoric for the first half of this century, a position that was fiercely contested and recently debunked by extensive studies carried out in the field of neuroregeneration research. The turning point came in the year 1928, when Ramon Y. Cajal\'s (Lobato, 2008) work suggested that the regenerative capacity of neurons, though limited, could exist beyond their physical being and depended on the environment surrounding them. That the manipulation of the restrictive environment surrounding the neuron could aid the regenerative process was conclusively established by Aguayo and colleagues (Richardson et al., 1980). Since then, various strategies have been employed to target the different phases of regeneration which include: cell-replacement and augmenting endogenous neurogenesis, the use of trophic factors, reversal of the inhibitory cues, and induction of signaling pathways that stimulate axon growth and guidance (Horner and Gage, 2000).

Replacement of damaged tissue with cell-grafts or pluripotent stem cells that could differentiate into neural and glial cell populations has been widely studied (Modo et al., 2002; Jiang et al., 2011). In light of the practical and ethical issues restraining the field of stem cell research, alternative modes of stimulating neurogenesis are highly sought after. We now know that neurogenesis is not only an ongoing process in adults, but it can also be induced by pathological conditions like traumatic brain injury and ischemic stroke (Greenberg, 2007; Yu et al., 2008). This field of research views the nervous system as a plastic entity that can respond to deleterious cues by triggering repair mechanisms (Okano et al., 2007). Neurogenesis is thus a valuable avenue for therapeutic efforts aimed at reducing disability and cognitive decline following ischemic stroke.

Neurogenesis in the adult brain involves the proliferation of precursor cells known as stem cells/neural progenitor cells (NSCs). The repositories for these NSCs are the sub-ventricular zone (SVZ), the sub-granular zone (SGZ) of the dentate gyrus (DG), and to a lesser extent, the posterior periventricular area (PPv) (Gage, 2000; Wiltrout et al., 2007). The NSCs of the SVZ are pluripotent and migrate as a chain of neuroblasts, forming the rostral migratory stream (RMS) that leads to the olfactory bulb, wherein they eventually differentiate to form interneurons (Alvarez-Buylla and Garcia-Verdugo, 2002). This property is retained even in the absence of the olfactory bulb, suggesting that it is not target-oriented (Kirschenbaum et al., 1999) and could thus be routed to serve other purposes. In the case of ischemia, the NSCs are not only known to proliferate but also to defy the RMS and move laterally toward the site of injury (Zhang et al., 2008). The SGZ of the dentate gyrus is the next important site of neurogenesis. Whether its stem cells are truly self-renewing or more lineage-restricted is a matter of contention (Gage et al., 1998), due to which they are referred to as progenitor cells. Both global and focal ischemia induce neurogenesis in the SVZ and the DG, with the focal mode thought to engage neurogenesis in the cortex as well (Wiltrout et al., 2007). The migration of these proliferating NSCs needs to be substantiated with sufficient neuronal differentiation and functional integration into the neural network in order to have a significant impact on the improvement of stroke outcomes. Though ischemia is a potent inducer of proliferation and migration of NSCs, it does not provide an environment conducive to their survival, differentiation and integration (Wiltrout et al., 2007; Niv et al., 2012). However, neurogenesis is a dynamic process and is sensitive to external cues like radiation and fatty diet that shut off the process, whereas exercise and caloric restriction upregulate or enhance it. This is beneficial from the therapeutic standpoint and has been utilized in several drug discovery efforts.

Natural products have been investigated for their ability to induce the proliferation, differentiation, migration and, finally, functional integration of neural stem cells in the hope of discovering a successful regenerative therapy for stroke. The polyvalent mode of action of most natural product-based drugs is particularly beneficial in a complex pathology like ischemia, wherein multiple destructive mechanisms need to be targeted simultaneously for an effective intervention (Wu et al., 2010). In addition to their diverse molecular targets, natural products also enjoy better absorption profiles when compared to purely synthetic leads. Recent advances in bioactivity-guided screening assays and reliable characterization techniques have improved the productivity of natural products tremendously, making them the most likely potential source of drug leads (Harvey, 2008). Many traditional herbs have been tested in experimental stroke models, some showing huge potential. Components of *Salviae Miltiorrhizae Radix* (Zhong et al., 2007), *Cornus officinalis* (Yao et al., 2009), *Ginkgo biloba* (G. biloba, Tchantchou et al., 2007; Nada et al., 2014), and some herbal combinations like NeuroAid (Heurteaux et al., 2010) are known to promote neurogenesis in conditions of ischemic and other pathological stress. Most of these natural products function by augmenting physiological repair mechanisms by increasing the synthesis of growth factors and stress-response elements.

G. biloba is a widely studied herb for the treatment of neurological disorders (Di Renzo, 2000); the neurogenesis-enhancing effects of G. biloba form the focus of this perspective. Its cellular mechanisms of action and the consequential regenerative effects outlined here would provide valuable insight into its therapeutic potential for stroke and various related disorders. The standardized extract of this herb, EGb 761, is prescribed as a dietary supplement and is touted to have neuroprotective and neurorestorative properties that have been consistently reproduced in many animal models of CNS disorders (Kehr et al., 2012; Diamond and Bailey, 2013; Tulsulkar and Shah, 2013; Wang et al., 2013a). Its use as a symptomatic treatment for dementia has been established in many preclinical studies (Tchantchou et al., 2007; Wang et al., 2013b) and clinical trials (Oken et al., 1998; Schneider et al., 2005; Mazza et al., 2006; Weinmann et al., 2010). A number of clinical studies conducted in Europe and the US have demonstrated the potential therapeutic effects of G. biloba in multi-infarct dementia, early or mild cognitive decline, and severe types of senile dementias (Weinmann et al., 2010; Amieva et al., 2013). However, "Ginkgo Evaluation of Memory (GEM)," showed no effect of EGb 761 (240 mg daily dose for 7 years) on delaying or preventing Alzheimer\'s-related dementia among the population aged 75 or older (DeKosky et al., 2006).

EGb 761 is standardized to contain 24% flavone glycosides and 6% terpenoids. Most of the neuroprotective effects of EGb 761 stem from its antioxidant effects, although its ability to increase cerebral blood flow and modulate neurotransmitter activity are also thought to be contributory (Diamond et al., 2000). Recent studies on the mechanisms of action of this extract have unraveled a host of other effects, many of which are not related to its anti-oxidant effects. This has broadened the scope of EGb 761 beyond the traditional realm of neuroprotection to the restorative and recovery potential for stroke therapy. An important, recently established example is the discovery of the multifaceted actions of EGb 761-mediated upregulation of hemeoxygenase 1 (HO1) (Shah et al., 2011; Nada and Shah, 2012; Nada et al., 2014). HO1 is a stress-inducible anti-oxidant enzyme responsible for catabolizing pro-oxidant heme into carbon monoxide, bilirubin and biliverdin. HO1 is crucial for anti-oxidant defense and is, more importantly, a viable target for stroke therapy. HO1 not only breaks down heme, but also most of its byproducts have neuroprotective properties (Ahmad et al., 2006), thus creating a milieu for HO1 upregulation to affect diverse signaling cascades.

We and others have unequivocally proven HO1 to be one of the prime targets of EGb 761-mediated protection, as observed in animal models of stroke and other conditions of oxidative stress (Chen et al., 2001; Zhuang et al., 2002; Saleem et al., 2008; Shah et al., 2011; Nada and Shah, 2012). EGb 761 enhances neurogenesis, and the crosstalk between HO1-induction and enhanced neurogenesis has only been recently discovered (Vanella et al., 2013; Nada et al., 2014). Our group demonstrated that EGb 761-treated mice not only showed an increase in the number of NSCs post-stroke, but also the majority of these NSCs were found in the proximity of the injury site or penumbra area. This was further evidenced by the upregulation of netrin-1 and its receptors, DCC and UNC5B, which mediate axonal attraction and repulsion. It is known that attractive and repulsive guidance cues dictate post-stroke axonal sprouting as well as migration of neuroblasts towards the site of the injury (Carmichael, 2008). Netrin-1 overexpression promotes neuronal migration and aids cell survival (Tang et al., 2008). Thus, EGb 761-mediated overexpression of netrin-1 signifies its ability to promote a suitable environment for the migration of neuroblasts. As previously discussed, the migration of newly formed NSCs alone would be less beneficial if not followed by neuronal differentiation and the survival of the NSCs upon reaching the target or injury site. We found that EGb 761 also enhanced the expression of Wnt, the ligand that is responsible for triggering the canonical Wnt pathway or the Wnt/β-catenin pathway, which constitutes one of the primary signaling mechanisms crucial for endogenous neurogenesis. Potentiation of the Wnt cascade is known to improve functional outcomes after stroke by increasing neuronal differentiation and survival of the newly formed neurons (Shruster et al., 2012). EGb 761-treated mice also showed upregulated expression of brain derived growth factor (BDNF) in NSCs, which is a specific marker for neuronal cells and enhances proliferation and differentiation of NSPCs (Nada et al., 2013) **(**[**Figure 1**](#F1){ref-type="fig"}**)**.

![Possible signaling of G. biloba (EGb 761) induced neuroprotection and neurogenesis.\
We propose that neuroprotective mechanism(s) of EGb 761 are mediated via multiple pathways: 1) EGb 761 activates hemeoxygenase 1 (HO1), which cleaves heme to form biliverdin and carbon monoxide (CO). CO increases intracellular cyclic guanosine monophosphate (cGMP) production, which mediates axon branching by activating chemoattractive semaphorin 3A (SEMA3A) and also by inhibiting glycogen synthase kinase 3 (GSK-3). GSK-3 inhibition increases the activity of collapsing response mediator protein-2 (CRMP-2), leading to cell survival and cell neuroplasticity; 2) EGb 761 activates the vascular endothelial growth factor (VEGF)/endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) pathway that leads to chemoattractant SEMA3A activation and angiogenesis; 3) EGb 761 increases Wnt and activates Wnt/β-catenin pathway and, by inhibiting GSK-3, leads to neurogenesis, proliferation and migration; 4) EGb 761 directly activates brain derived neurotrophic factor (BDNF) and increases cell survival and neuroplasticity; and 5) EGb 761 activates netrin 1 and its receptors deleted in colorectal cancer (DCC) and uncoordinated gene 5B (UNC5B), leading to increased neurogenesis, proliferation and migration. Activation (⟶), inhibition (⊣), mutual activation (⟷).\
(Figure modified from Nada et al. *Molecular Neurobiology*. 2014;49:945-956.)](NRR-9-1104-g001){#F1}

Quite interestingly, our group also found that neurogenesis was significantly diminished in HO1 knockout mice seven days post-surgery. This finding corroborates with our earlier studies that HO1 knockout mice were not protected by ischemic preconditioning (Zeynalov et al., 2009) and suffered from higher infarct volume and severe neurologic deficits after seven days of permanent ischemia (Shah et al., 2011). Since HO1 is an essential target of EGb 761\'s action, we were curious to learn whether EGb 761-mediated HO1 induction had a role to play in its neurogenesis-enhancing properties. We have highly plausible explanations to establish the link between the two. For example, it is well known that HO1 is an inducer of vascular endothelial growth factor (VEGF) (Cisowski et al., 2005; Lin et al., 2011), which is not only a promoter of angiogenesis but also has neurogenic properties (Sun et al., 2003). Thus HO1 seems to act on the neurovascular niche that supports the newly formed neurons as well as the vasculature surrounding the network. We have previously demonstrated that EGb 761 upregulates the expression of VEGF concomitant with that of HO1 (Shah et al., 2011). In addition, we have established the link between HO1 and collapsin response mediator protein 2 (CRMP2) in a study examining its neuritogenic potential (Nada and Shah, 2012). CRMP2 is a protein involved in neuronal development and neurite outgrowth, the inactivation of which is known to cause growth cone collapse (Crews et al., 2011; Higurashi et al., 2012). The positive correlation between HO1 and CRMP2 expression further substantiates the involvement of HO1 in neurogenesis. Lastly, the discovery that HO1 acts upstream of the Wnt signaling pathway (Vanella et al., 2013) strongly ties the augmented neurogenesis seen in our study to HO1 upregulation and also highlights how a single protein could perturb multiple signaling mechanisms ([**Figure 1**](#F1){ref-type="fig"}). To support our preclinical studies, a recent double-blind, placebo-controlled and randomized clinical study for the first time recommended the use of G. biloba in stroke recovery. G. biloba (120 mg daily) treatment for 4 months following an ischemic stroke significantly reduced NIHSS in stroke patients compared to the placebo group (Oskouei et al., 2013). In order to promote the wide and safe use of G. biloba, further high quality and large-scale randomized controlled trials are warranted to test its efficacy in acute ischemic stroke recovery.

Stroke is a leading cause of long-term disability and poses excruciating economic and societal burdens (Go et al., 2014). Therapies aimed at post-stroke recovery may help curb the rising cost of healthcare and are therefore highly sought after. To treat complex neurodegenerative diseases, polypharmacology is a well sought strategy, and natural products, particularly extracts, can offer a treasure of potential drug leads that could someday change the way we think of neuro-regeneration and the use of medicinal plants.
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